Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

MenoZen VR for Menopause Symptom Management: Phase 2

NCT: NCT07633743 · NOT_YET_RECRUITING

NCT IDNCT07633743
StatusNOT_YET_RECRUITING
Start Date2026-07-31
Completion2028-07-31
SponsorMayo Clinic (OTHER)
First posted
Last updated

Brief Summary

The purpose of this research is to evaluate the feasibility, acceptability, tolerability, and clinical efficacy of MenoZen VR (virtual reality) for managing menopause symptoms in women.

Frequently Asked Questions

What is MenoZen VR for Menopause Symptom Management: Phase 2?

MenoZen VR for Menopause Symptom Management: Phase 2 is a clinical trial registered under NCT07633743. Current status: NOT_YET_RECRUITING.

What is the status of NCT07633743?

The current status of NCT07633743 (MenoZen VR for Menopause Symptom Management: Phase 2) is: NOT_YET_RECRUITING.

When did MenoZen VR for Menopause Symptom Management: Phase 2 start?

MenoZen VR for Menopause Symptom Management: Phase 2 started on 2026-07-31.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑